NCT06543836招募中2 期
ctDNA-guided Treatment of an Anti-angiogenic TKI Combined With a PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer Failed With Standard Therapy: a Randomized Controlled Phase 2 Clinical Trial
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2023年12月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
The efficacy of combining TKI with PD-1 inhibitor in the treatment of advanced MSS/pMMR colorectal cancer with low levels of maxVAF in peripheral blood ctDNA failed with standard treatment was assessed, compared to standard treatment as chosen by researchers.
详细描述
This study is a prospective, randomized phase II controlled trial. It will include patients with histologically confirmed advanced metastatic pMMR/MSS colorectal adenocarcinoma, who have failed with treatment with fluoropyrimidine (5-fluorouracil or capecitabine), oxaliplatin, irinotecan plus bevacizumab/cetuximab (left-side RAS/BRAF wild-type) and whose peripheral blood ctDNA test shows a maxVAF level lower than 6.5%. Patients will be randomly assigned to receive a TKI + a PD-1 inhibitor (primarily fruquintinib combined with sintilimab) or standard later-line treatment options (regorafenib or fruquintinib monotherapy, at the discretion of the investigator) until disease progression, death, intolerable adverse events, or withdrawal of informed consent.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age range between 18 and 80 years old.
- •ECOG performance status of 0 or
- •Histologically confirmed advanced or recurrent colorectal adenocarcinoma.
- •Confirmed normal expression of mismatch repair proteins (pMMR) by immunohistochemistry or microsatellite stable (MSS) by PCR/next-generation sequencing.
- •Blood ctDNA maxVAF <6.5% as detected by NGS. blood samples of 8-10ml are to be collected from a qualified testing company for analysis.
- •Metastatic colorectal cancer that has failed with previous treatment with fluoropyrimidine (5-fluorouracil or capecitabine), oxaliplatin, irinotecan plus bevacizumab/cetuximab (left-side RAS/BRAF wildtype).
- •At least 28 days since the last systemic therapy (oral fluoropyrimidine ≥ 14 days), with the option of receiving palliative radiation therapy to limited areas if completed more than 3 weeks prior.
- •At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST V1.1).
- •Expected survival of at least 3 months.
- •Adequate organ and bone marrow function, with laboratory values within the following limits within 7 days before enrollment:
- •Complete blood count: Absolute neutrophil count (ANC) ≥1.5×10^9/L, Platelet count (PLT) ≥100×10^9/L, Hemoglobin (HGB) ≥9.0 g/dL.
- •Liver function: Total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5× ULN, or ≤5× ULN in the presence of liver metastasis.
- •Kidney function: Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥50ml/min, Urinalysis showing urine protein <2+, for patients with baseline urine protein ≥2+, 24-hour urine protein collection should show <1g.
- •Coagulation function: International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5 times ULN.
- •Normal electrocardiogram, left ventricular ejection fraction (LVEF) ≥50%.
- •No history of other malignancies, except for cured cervical carcinoma in situ, non-melanoma skin cancer, non-invasive bladder tumors, non-invasive lung cancer, or malignant tumors with continuous disease-free survival of ≥5 years following surgical resection.
- •Negative pregnancy test for women of childbearing potential, and willingness to use effective contraception during the clinical trial period.
- •Voluntary participation in the clinical trial with informed consent provided.
排除标准
- •Patients with a history of prior treatment with fruquintinib or similar small molecule oral targeted drugs primarily aimed at anti-angiogenesis (including marketed or investigational drugs).
- •Patients with a history of prior treatment with other PD-1/PD-L1/CTLA-4 antibody therapies or other immunotherapies targeting PD-1/PD-L1/CTLA-
- •Patients who experienced severe hypersensitivity reactions after monoclonal antibody administration in the past.
- •Patients with any active autoimmune disease or a history of autoimmune diseases (such as, but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis, and patients requiring bronchodilators for medical intervention for asthma cannot be included). however, the following patients are allowed to be included: patients with vitiligo, psoriasis, alopecia that do not require systemic treatment, well-controlled type I diabetes, and hypothyroidism with normal thyroid function under replacement therapy.
- •Patients who require immunosuppressive agents, systemic corticosteroids, or absorbable local steroid therapy for achieving immunosuppression (dose >10mg/day prednisone or equivalent) and are still on continued therapy within 2 weeks of initial dosing.
- •Patients with various factors affecting oral drug intake (such as dysphagia, post-gastrointestinal surgery, chronic diarrhea, and intestinal obstruction).
- •Patients with uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
- •Patients with any signs or history of bleeding diathesis regardless of severity, patients who experienced any bleeding event ≥CTCAE Grade 3 within 4 weeks before initial dosing, or patients with unhealed wounds, fractures, active peptic ulcers, ulcerative colitis, or other gastrointestinal diseases with active bleeding or other conditions deemed by the investigator to potentially cause severe gastrointestinal bleeding or perforation.
- •Patients with known brain metastases with a history of organ transplantation.
- •Patients who received approved or investigational anti-tumor treatments within 4 weeks before the start of the study, including but not limited to chemotherapy, surgery, radiotherapy (within 3 weeks), biologically targeted therapy, interventional therapy, immunotherapy, and traditional Chinese medicine treatment for cancer (as per the indications in the traditional Chinese medicine instructions, participants can be included after a 2-week washout period) (Note: oral fluoropyrimidine drugs for less than 14 days, patients with adverse events from previous treatments, excluding alopecia, not recovered to ≤CTCAE Grade 1).
- •Patients vaccinated with preventive or attenuated vaccines within 4 weeks before the first dose.
- •Patients with any severe and/or uncontrolled diseases, including:
- •patients with suboptimal blood pressure control (systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥90 mmHg).
- •patients who had thrombotic events, cerebrovascular accidents, myocardial infarctions, ≥Grade 2 congestive heart failure, or requiring treatment for arrhythmias (including QTc ≥480ms) within 6 months before the first dose.
- •patients with active or uncontrolled severe infections (≥CTCAE Grade 2 infections), tuberculosis patients.
- •patients with a clinically significant history of liver disease, including viral hepatitis, known carriers of hepatitis B virus (HBV) must exclude active HBV infection, i.e., HBV DNA positive (>1 × 10^4 copies/mL or >2000 IU/mL), known hepatitis C virus infection (HCV) and HCV RNA positive (>1 × 10^3 copies/mL), or other decompensated liver diseases, chronic hepatitis requiring antiviral treatment.
- •HIV positive.
- •poorly controlled diabetes (fasting blood sugar ≥CTCAE Grade 2).
研究组 & 干预措施
PD-1 inhibitor+Tyrosine kinase inhibitor(TKI)
Experimental
PD-1 inhibitor: Sintilimab 200mg, d1, TKI: Fruquintinib 5mg Qd, d1-14, Q3w. Efficacy assessment every 2 cycles.
干预措施: Sintilimab (Drug)
PD-1 inhibitor+Tyrosine kinase inhibitor(TKI)
Experimental
PD-1 inhibitor: Sintilimab 200mg, d1, TKI: Fruquintinib 5mg Qd, d1-14, Q3w. Efficacy assessment every 2 cycles.
干预措施: Fruquintinib (Drug)
Tyrosine kinase inhibitor(TKI)
Active Comparator
The treatment regimen consists of the following options:
Option 1: Fruquintinib 5mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.
Option 2: Regorafenib 160mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.
干预措施: Fruquintinib or Regorafenib (Drug)
结局指标
主要结局
PFS
时间窗: Up to 2 years
Progression-free survival
次要结局
- OS(Up to 2 years)
- ORR(Up to 2 years)
- DCR(Up to 2 years)
研究者
AIPING ZHOU
Professor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCCHepatocellular CarcinomaNCT04639284Shanghai Zhongshan Hospital200
招募中
2 期
Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal CancerMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)Neoadjuvant TherapyColorectal CancerNCT03926338Sun Yat-sen University270
已完成
2 期
Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal CancerColorectal CancerNCT05414461First Affiliated Hospital of Zhejiang University97
进行中（未招募）
2 期
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal CancerDMMR Colorectal CancerMSI-H Colorectal CancerLocally Advanced Colorectal CancerNCT04301557Sun Yat-sen University25
招募中
不适用
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal PatientsColorectal CancerNCT06098560Geneplus-Beijing Co. Ltd.60